Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19

Patients with COVID-19 may present a hypercoagulable state, with an important impact on morbidity and mortality. Because of this situation pulmonary embolism is a frequent complication during the course of infection. We present the case of a patient recently discharged, after admission with confirme...

Descripción completa

Detalles Bibliográficos
Autores principales: Llopis Gisbert, Guillem, Vidal Urrutia, Verónica, Moruno Benita, Miguel A., Payá Chaume, Ana, Berenguer Jofresa, Alberto, Cubillos Arango, Andrés M., Pérez Boscá, José L., Payá Serrano, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Canadian Cardiovascular Society. Published by Elsevier Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585166/
https://www.ncbi.nlm.nih.gov/pubmed/33485934
http://dx.doi.org/10.1016/j.cjca.2020.10.008
Descripción
Sumario:Patients with COVID-19 may present a hypercoagulable state, with an important impact on morbidity and mortality. Because of this situation pulmonary embolism is a frequent complication during the course of infection. We present the case of a patient recently discharged, after admission with confirmed COVID-19, who developed a pulmonary embolism and thrombosis of a biological mitral valve prosthesis, producing valve obstruction and stenosis. After 15 days of anticoagulant treatment, resolution of the thrombus and normalisation of prosthetic valve function was observed. This case supports current recommendations of administering full-dose anticoagulation therapy to COVID-19 patients with biological heart valve prosthesis, even after the acute phase of infection.

Ejemplares similares